Indian state plans non-generic drugs procurement for government hospitals

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Ensuring Regulatory Compliance in Pharmaceutical QC Labs

Ensuring regulatory compliance in pharmaceutical Quality Control labs requires advanced analytical capabilities, robust data integrity systems, and strict adherence to evolving global GMP standards. By integrating lifecycle-based method validation, digital traceability, and ultra-trace impurity detection, QC laboratories safeguard product quality and patient safety at every stage of manufacturing.

Integrated Health Risk Assessment in Food and Pharma Sectors

Integrated health risk assessment in food and pharma sectors aligns toxicology, exposure modeling, and regulatory standards to address cumulative chemical risks across daily consumption and therapy. By harmonizing methodologies and leveraging shared data, regulators and manufacturers can build a more holistic, science-driven safety framework that protects long-term public health.

Advanced Analytical Technologies in Pharma Impurity Testing

Advanced analytical technologies in pharma impurity testing are transforming how trace contaminants are detected, identified, and controlled across the drug lifecycle. With high-resolution instrumentation, automation, and AI-driven insights, the industry is strengthening precision, data integrity, and patient safety to meet increasingly stringent purity standards.
- Advertisement -

Indian state of Uttar Pradesh is planning to procure non-generic drugs directly from the manufacturing companies for usage in government hospitals in the state.

The state government is formulating a new drug policy that will allow the state health department to procure these drugs for government hospitals, unlike earlier the department used to procure only generic drugs manufactured by companies selected in the drug tender process at the state level.

Principal Secretary of Health and Family Welfare Sanjay Agarwal was quoted by expressindia.com as saying that the idea behind procurement of non-generic drugs is to provide the best quality drugs for chronic diseases in government hospitals.

“The proposal was approved by state’s Health Minister Ahmad Hasan, who wanted that the best quality drugs should also reach the poor people,” said Agarwal.

The state government has allocated a budget of INR45 crore ($8.13m) for procurement of 22 non-generic drugs listed by the department, which will used for ailments like diabetes, cardiac disease, blood pressure as well as some essential anti-biotic drugs, reports the website.

“The companies will enter into a contract with the department wherein they will have to certify that they would not sell these drugs to any other party at a cost lower than the price they are supplying the drugs to UP,” he added.

The non-generic drugs, to be procured by the department, will cost about half the cost of drugs available in the market, according to Agarwal.

Latest stories

Related stories

Ensuring Regulatory Compliance in Pharmaceutical QC Labs

Ensuring regulatory compliance in pharmaceutical Quality Control labs requires advanced analytical capabilities, robust data integrity systems, and strict adherence to evolving global GMP standards. By integrating lifecycle-based method validation, digital traceability, and ultra-trace impurity detection, QC laboratories safeguard product quality and patient safety at every stage of manufacturing.

Integrated Health Risk Assessment in Food and Pharma Sectors

Integrated health risk assessment in food and pharma sectors aligns toxicology, exposure modeling, and regulatory standards to address cumulative chemical risks across daily consumption and therapy. By harmonizing methodologies and leveraging shared data, regulators and manufacturers can build a more holistic, science-driven safety framework that protects long-term public health.

Advanced Analytical Technologies in Pharma Impurity Testing

Advanced analytical technologies in pharma impurity testing are transforming how trace contaminants are detected, identified, and controlled across the drug lifecycle. With high-resolution instrumentation, automation, and AI-driven insights, the industry is strengthening precision, data integrity, and patient safety to meet increasingly stringent purity standards.

Managing PFAS Regulations in Pharmaceutical Supply Chains

PFAS regulations in pharmaceutical supply chains are reshaping how critical materials are sourced, validated, and justified amid rising environmental scrutiny. Manufacturers must balance sustainability, regulatory compliance, and material performance to ensure uninterrupted delivery of safe and effective medicines.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »